Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart, Inc. (Nasdaq: VXRT) announced that its Chief Scientific Officer, Dr. Sean Tucker, and Senior Scientist, Dr. Rebecca Flitter, will present data on its COVID-19 oral tablet vaccine at the International Congress of Mucosal Immunology 2022, scheduled for July 16-20 in Seattle. On July 18, Dr. Tucker will discuss oral vaccination's ability to induce pan-coronavirus nasal IgA responses, while Dr. Flitter will present findings on mucosal rAd5 immunization against SARS-CoV-2, showcasing its effectiveness in non-human primates.
Vaxart, Inc. (Nasdaq: VXRT) is urging stockholders to vote on Proxy Proposal #2 by July 5, 2022, which seeks to increase authorized shares to 250 million. This proposal is backed by ISS and Glass Lewis, indicating strong support. Currently, 76% of present voting shares favor the proposal, but it requires more than 50% of all outstanding shares to pass. CEO Andrei Floroiu emphasizes that approval would enhance capital-raising flexibility, aiding Vaxart's promising pipeline and competitive position. Stockholders can vote online, by phone, or via mail.
Vaxart, Inc. (Nasdaq: VXRT) has entered an agreement with hVIVO Services Limited to develop a human challenge model based on the Omicron variant of SARS-CoV-2. This initiative aims to support a Phase II Human Challenge Trial of Vaxart's oral COVID-19 vaccine pill candidate. Vaxart is pioneering the use of an Omicron-specific challenge study, making it the first company to do so. The successful execution of the challenge study is expected to start in 2023, contingent upon regulatory approvals.
Vaxart, Inc. (Nasdaq: VXRT) announced a Q&A webcast with investors and analysts on June 22, 2022, at 1:00 p.m. ET, featuring CEO Andrei Floroiu, SVP Dr. Sean Tucker, and CMO Dr. James Cummings. They will discuss the company's oral vaccine programs and answer submitted questions. The event will be available for replay two hours after its conclusion on Vaxart's website. Additionally, Vaxart’s 2022 annual meeting has been rescheduled to July 6, 2022, at 12:30 p.m. ET, encouraging stockholders to vote by July 5, 2022.
Vaxart, Inc. (Nasdaq: VXRT) has announced the adjournment of its 2022 annual meeting of stockholders to July 6, 2022, at 9:30 a.m. PT. Stockholders of record as of April 11, 2022, are encouraged to vote by July 5, 2022, at 11:59 p.m. ET. Approximately 58.22% of shares were voted, with key proposals mostly approved, except for an amendment to increase authorized shares. This amendment's failure may hinder Vaxart's abilities in raising capital and strategic planning. The meeting will be accessible via live webcast.
Vaxart (NASDAQ: VXRT) reported promising preliminary preclinical data for its COVID-19 vaccine candidates targeting the SARS-CoV-2 variants. Both the Wuhan and Omicron specific vaccines demonstrated protective effects in hamsters against the Omicron BA.1 variant, with the Omicron candidate showing superior antibody response. Weight loss and viral load were reduced in vaccinated animals compared to unvaccinated ones. Vaxart continues to leverage evolving pandemic data for vaccine development strategies, advancing toward clinical trials.
Vaxart (NASDAQ: VXRT) announced positive preliminary results from its Phase 1b trial of an oral norovirus vaccine for adults aged 55 to 80. The study showed a robust immune response with a dose-dependent increase in IgA antibody secreting cells, alongside a favorable safety profile. These results support the development of the vaccine in elderly populations. The company is conducting a Phase 2 clinical challenge study and reported encouraging data from a booster study, allowing for improved antibody responses. Norovirus costs the U.S. healthcare system an estimated $10.6 billion annually.
Vaxart, Inc. (Nasdaq: VXRT) announced that its leadership team, including CEO Andrei Floroiu, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. The event will be streamed live on the Company’s website, with a replay available afterward. Vaxart specializes in developing oral recombinant vaccines and is currently working on vaccines targeting coronavirus, norovirus, seasonal influenza, and RSV, among others. The company is committed to innovative delivery methods for vaccines that require no refrigeration.
Vaxart (NASDAQ: VXRT) announced significant findings from a preclinical hamster study, suggesting its S-only oral COVID-19 vaccine candidate effectively inhibits SARS-CoV-2 transmission. The study highlighted a reduction in infectious virus and transmission among vaccinated hamsters. Additionally, Phase 1 results showed the S+N vaccine candidate stimulated cross-reactive IgA antibodies, indicating potential effectiveness against various coronaviruses. The results were published in Science Translational Medicine, reinforcing Vaxart's oral vaccine development strategy. Future Phase II results are expected later this year.
Vaxart, Inc. (NASDAQ: VXRT) reported an update for Q1 2022, highlighting progress on oral vaccine candidates, including norovirus and COVID-19. The company ended the quarter with $157.0 million in cash and reported a net loss of $25.1 million, up from $16.0 million a year prior. Revenue fell to $85,000 from $506,000 year-over-year, primarily due to decreased royalty revenue. Key results from clinical trials for its COVID-19 and norovirus vaccines are expected in the upcoming quarters.